Stay updated on Stereotactic RT+Pembrolizumab in Oligometastatic Renal Cancer Clinical Trial
Sign up to get notified when there's something new on the Stereotactic RT+Pembrolizumab in Oligometastatic Renal Cancer Clinical Trial page.

Latest updates to the Stereotactic RT+Pembrolizumab in Oligometastatic Renal Cancer Clinical Trial page
- Check4 days agoChange DetectedAdded Revision: v3.4.2. Removed older notices about government funding lapse and NIH Clinical Center operating status; users are directed to opm.gov for current status updates.SummaryDifference0.4%

- Check11 days agoChange DetectedAdded a government funding lapse notice and updated the revision tag from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check18 days agoChange DetectedAdded a 'Show glossary' option and standardized several footer/labels: 'Last Update Submitted that Met QC Criteria', 'No FEAR Act Data', and updated the Revision tag to v3.4.0 (from v3.3.4).SummaryDifference0.2%

- Check32 days agoChange DetectedRevision: v3.3.4 is now displayed, replacing Revision: v3.3.3. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check53 days agoChange DetectedLocations section updated to include Queensland and Victoria as study sites; the page revision updated to v3.3.3.SummaryDifference0.3%

- Check82 days agoChange DetectedThe Publications section now clarifies that PubMed-sourced publications are auto-filled and linked to the NCT number. It specifies the origin of these entries and how they relate to the study record.SummaryDifference0.1%

Stay in the know with updates to Stereotactic RT+Pembrolizumab in Oligometastatic Renal Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Stereotactic RT+Pembrolizumab in Oligometastatic Renal Cancer Clinical Trial page.